Candriam S.C.A. Trims Stock Holdings in Halozyme Therapeutics, Inc. $HALO

Candriam S.C.A. lowered its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 8.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 79,983 shares of the biopharmaceutical company’s stock after selling 7,439 shares during the quarter. Candriam S.C.A. owned about 0.07% of Halozyme Therapeutics worth $5,866,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in HALO. DLD Asset Management LP acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter worth approximately $650,250,000. Arrowstreet Capital Limited Partnership raised its position in Halozyme Therapeutics by 127.8% in the second quarter. Arrowstreet Capital Limited Partnership now owns 2,541,181 shares of the biopharmaceutical company’s stock valued at $132,192,000 after purchasing an additional 1,425,674 shares during the period. Federated Hermes Inc. lifted its stake in Halozyme Therapeutics by 294.1% during the third quarter. Federated Hermes Inc. now owns 1,450,704 shares of the biopharmaceutical company’s stock worth $106,395,000 after purchasing an additional 1,082,638 shares in the last quarter. Qube Research & Technologies Ltd purchased a new position in shares of Halozyme Therapeutics during the second quarter worth $51,295,000. Finally, Los Angeles Capital Management LLC grew its stake in shares of Halozyme Therapeutics by 951.8% in the second quarter. Los Angeles Capital Management LLC now owns 973,670 shares of the biopharmaceutical company’s stock valued at $50,650,000 after buying an additional 881,094 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

HALO has been the topic of several research reports. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, January 29th. Morgan Stanley reduced their price target on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a research report on Monday, October 20th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 31st. TD Cowen upped their target price on shares of Halozyme Therapeutics from $79.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Finally, Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, February 3rd. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $78.80.

Halozyme Therapeutics Trading Down 0.9%

Shares of NASDAQ:HALO opened at $79.51 on Thursday. Halozyme Therapeutics, Inc. has a 52 week low of $47.50 and a 52 week high of $82.22. The company’s 50 day moving average is $70.25 and its two-hundred day moving average is $69.62. The company has a current ratio of 1.59, a quick ratio of 1.37 and a debt-to-equity ratio of 1.59. The company has a market cap of $9.35 billion, a PE ratio of 16.74, a P/E/G ratio of 0.33 and a beta of 0.97.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 2,000 shares of the firm’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $70.25, for a total value of $140,500.00. Following the sale, the director directly owned 40,123 shares in the company, valued at $2,818,640.75. This trade represents a 4.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $76.12, for a total value of $1,522,400.00. Following the transaction, the chief executive officer directly owned 708,719 shares of the company’s stock, valued at approximately $53,947,690.28. This represents a 2.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 49,398 shares of company stock worth $3,650,592 in the last three months. 2.40% of the stock is currently owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.